Lymphocyte infiltration in CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy

Clinical Ophthalmology

Volumn 7, Issue , 2013, Pages 1339-1345

  Mahajan, Vinit B ^a,b   Lin, Jonathan H ^c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

ADNIV; Autosomal dominant neovascular inflammatory vitreoretinopathy; CAPN5; CD3; Uveitis

Indexed keywords

CALPAIN 5; CD3 ANTIGEN; CYSTEINE PROTEINASE; LEUCINE; PROLINE; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CAPN5 GENE; CASE REPORT; CELL INFILTRATION; DISEASE SEVERITY; ENUCLEATION; EYE DISEASE; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPATHOLOGY; LYMPHOCYTIC INFILTRATION; MALE; OCULAR FIBROSIS; PHTHISIS BULBI; RETINA; RETINA DETACHMENT; RETINA NEOVASCULARIZATION; T LYMPHOCYTE; UVEA; UVEITIS; VITREORETINOPATHY; VITREOUS BODY;

EID: 84879716034     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S46450     Document Type: Article

References (13)

1. Mahajan VB, Skeie JM, Bassuk AG, et al. Calpain-5 mutations cause autoimmune uveitis, retinal neovascularization, and photoreceptor degeneration. PLoS Genet. Epub October 4, 2012.
2. Bennett SR, Folk JC, Kimura AE, Russell SR, Stone EM, Raphtis EM. Autosomal dominant neovascular inflammatory vitreoretinopathy. Ophthalmology. 1990;97:1125-1135.
3. Tlucek PS, Folk JC, Orien JA, Stone EM, Mahajan VB. Inhibition of neovascularization but not fibrosis with the fluocinolone acetonide implant in autosomal dominant neovascular inflammatory vitreoretinopathy. Arch Ophthalmol. 2012;130(11):1395-1401.
4. Rowell HA, Bassuk AG, Mahajan VB. Monozygotic twins with CAPN5 autosomal dominant neovascular inflammatory vitreoretinopathy. Clin Ophthalmol. 2012;6:2037-2044.
5. Mahajan VB, Vallone JG, Lin JH, et al. T-cell infiltration in autosomal dominant neovascular inflammatory vitreoretinopathy. Mol Vis. 2010;16:1034-1040.
6. Tlucek PS, Folk JC, Sobol WM, Mahajan VB. Surgical management of fibrotic encapsulation of the fluocinolone acetonide implant in CAPN5-associated proliferative vitreoretinopathy. Clin Ophthalmol. 2013;7:1093-1098.
7. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev. 2003;83:731-801.
8. Sato K, Kawashima S. Calpain function in the modulation of signal transduction molecules. Biol Chem. 2001;382:743-751.
9. Zatz M, Starling A. Calpains and disease. N Engl J Med. 2005;352: 2413-2423.
10. Huang Y, Wang KK. The calpain family and human disease. Trends Mol Med. 2001;7:355-362.
11. Richard I, Broux O, Allamand V, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81:27-40.
12. Azuma M, Shearer TR. The role of calcium-activated protease calpain in experimental retinal pathology. Surv Ophthalmol. 2008;53:150-163.
13. Franz T, Winckler L, Boehm T, Dear TN. Capn5 is expressed in a subset of T cells and is dispensable for development. Mol Cell Biol. 2004;24:1649-1654.